Vanadocene-mediated in vivo male germ cell apoptosis

O J D'Cruz1, F M Uckun

  • 1Drug Discovery Program, Parker Hughes Institute, St. Paul, Minnesota 55113, USA. odcruz@ih.org

Insights

Vanadocenes effectively induce male germ cell apoptosis in mouse testes, causing reduced sperm counts and testicular atrophy. This suggests potential for treating human testicular seminomas.

Area of Science:

  • Organometallic Chemistry
  • Toxicology
  • Reproductive Biology

Background:

  • Vanadocenes exhibit potent apoptosis-inducing cytotoxic properties against human testicular cancer cells in vitro.
  • Understanding the in vivo effects of vanadocenes on male germ cells is crucial for therapeutic development.

Purpose of the Study:

  • To investigate the in vivo efficacy of four vanadocene compounds in inducing male germ cell apoptosis in mouse testes.
  • To evaluate the impact of repetitive intratesticular vanadocene injections on sperm count, testicular weight, and histology.

Main Methods:

  • Repetitive intratesticular injection of four vanadocene derivatives (VDA, VDCN, VDOCN, VDCO) at 7.5 mg/kg/testis for 28 days in mice.
  • Assessment of germ cell loss through epididymal sperm counts, testes weights, and histopathological examination.
  • In situ apoptosis detection using terminal deoxynucleotidyl transferase-mediated FITC-deoxyuridine triphosphate nick-end labeling (TUNEL) assay and laser confocal microscopy.

Main Results:

  • Vanadocene treatment resulted in significantly decreased sperm counts and reduced testicular weights.
  • Histopathology revealed seminiferous tubular atrophy, inhibited spermatogenesis, and preferential loss of maturing/elongated spermatids.
  • TUNEL assay identified pachytene spermatocytes at the seminiferous tubule periphery as characteristic apoptotic cells.

Conclusions:

  • Vanadocenes induce germ cell apoptosis in vivo, targeting specific meiotic and post-meiotic germ cell populations.
  • The findings suggest that vanadocenes hold potential therapeutic utility for treating testicular seminomas in humans.

Related Concept Videos

In-vitro Mutagenesis01:16

In-vitro Mutagenesis

To learn more about the function of a gene, researchers can observe what happens when the gene is inactivated or “knocked out,” by creating genetically engineered knockout animals. Knockout mice have been particularly useful as models for human diseases such as cancer, Parkinson’s disease, and diabetes.
Spermatogenesis01:41

Spermatogenesis

Spermatogenesis is the process by which haploid sperm cells are produced in the male testes. It starts with stem cells located close to the outer rim of seminiferous tubules. These spermatogonial stem cells divide asymmetrically to give rise to additional stem cells (meaning that these structures “self-renew”), as well as sperm progenitors, called spermatocytes. Importantly, this method of asymmetric mitotic division maintains a population of spermatogonial stem cells in the male reproductive...
Meiosis I03:09

Meiosis I

Meiosis is the division of a diploid cell into haploid cells forming sperm and eggs in animals through differentiation. Meiosis I is the first stage of meiosis, where the genetic recombination of homologous chromosomes and the reduction of the ploidy level by half occurs.
Prophase I is the most extended and complex step of meiosis I characterized by synapsis, chromosome pairing, and recombination of the homologous chromosomes. This process is facilitated by a proteinaceous structure called the...
Nondisjunction01:21

Nondisjunction

Nondisjunction is the failure of homologous chromosomes or sister chromatids to separate correctly and move to the opposite poles of the cells. This produces daughter cells with abnormal chromosome numbers.  Nondisjunction is common during anaphase I or anaphase II of meiosis.  Mutations in synaptonemal complex proteins that attach homologous chromosomes increase the chances of nondisjunction in anaphase I of meiosis I. In contrast, mutations in topoisomerases and condensins that hold sister...
Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...